Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
VHR
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "VHR" in MCE Product Catalog:
Cat. No.: HY-W099617
CAS No.: 2277-23-8
Synonyms: 1-Decanoyl-rac-glycerol
Research Areas:
2,3-Dihydroxypropyl decanoate (1-Decanoyl-rac-glycerol) is a derivative of Decanoic acid (HY-W015309) and a non-ionic surfactant, with an IC50 > 100 μM against Shp2-PTP, VHR and HePTP. 2,3-Dihydroxypropyl decanoate is found in the roots of Angelica dahurica (Baizhi). 2,3-Dihydroxypropyl decanoate acts as a component of reverse micelle systems for the encapsulation of proteins and nucleic acids .
Target:
RK-682 is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24 .
Cat. No.: HY-178292
CAS No.: 1191105-54-0
Target:
Research Areas:
VHR-IN-3 (Compound 1) is a selective vaccinia H1-related (VHR) phosphatase inhibitor with a Ki of 0.81 μM. VHR-IN-3 mimics the phosphate group through the sulfonic acid group and competitively binds to the catalytic active center of VHR. VHR-IN-3 can be used for the research of cervical cancer .
Cat. No.: HY-178285
CAS No.: 1146616-14-9
Target:
Research Areas:
VHR-IN-2 (Compound SA9) is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 3.1 μM. VHR-IN-2 can be used for the research of cervical cancer .
Cat. No.: HY-178296
CAS No.: 1146616-16-1
Target:
Research Areas:
VHR-IN-6 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 74 nM. VHR-IN-6 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.52 μM), CD45 (IC50 = 0.50 μM), Cdc25A (IC50 = 2.8 μM), PTP1B (IC50 = 0.42 μM), and HePTP (IC50 = 0.87 μM). VHR-IN-6 inhibits the proliferation of HeLa cells. VHR-IN-6 can be used for the research of cervical cancer .
Cat. No.: HY-178297
CAS No.: 1146616-17-2
Target:
Research Areas:
VHR-IN-7 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 71 nM. VHR-IN-7 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.47 μM), CD45 (IC50 = 0.3 μM), Cdc25A (IC50 = 3.4 μM), PTP1B (IC50 = 0.59 μM), and HePTP (IC50 = 1.2 μM). VHR-IN-7 inhibits the proliferation of HeLa cells. VHR-IN-7 can be used for the research of cervical cancer .
Cat. No.: HY-178301
CAS No.: 1146616-18-3
Target:
Research Areas:
VHR-IN-9 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 270 nM. VHR-IN-9 shows very weaker inhibitory activity against MKP-1 (IC50 = 2.8 μM), CD45 (IC50 = 1.8 μM), Cdc25A (IC50 = > 10 μM), PTP1B (IC50 = 2.2 μM), and HePTP (IC50 = 2.4 μM). VHR-IN-9 inhibits the proliferation of HeLa cells. VHR-IN-9 can be used for the research of cervical cancer .
Cat. No.: HY-178294
CAS No.: 1146616-15-0
Target:
Research Areas:
VHR-IN-4 (Compound SA7) is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 1.8 μM. VHR-IN-4 can be used for the research of cervical cancer .
Target:
Research Areas:
JUN-1111 is an irreversible and selective Cdc25 phosphatase inhibitor with IC50 values of 0.38, 1.8, 0.66, 28, 37 µM for Cdc25A, Cdc25B, Cdc25C, VHR, PTP1B, respectively. JUN-1111 induces cell cycle arrest at G1 and G2/M phases. JUN-1111 decreases the expression of phosphoCdk1 .
Cat. No.: HY-178303
CAS No.: 1146616-19-4
Target:
Research Areas:
VHR-IN-8 (Compound SA8) is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 2.4 μM. VHR-IN-8 can be used for the research of cervical cancer .
Cat. No.: HY-178295
CAS No.: 956442-05-0
Target:
Research Areas:
VHR-IN-5 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 78 nM. VHR-IN-5 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.78 μM), CD45 (IC50 = 0.61 μM), Cdc25A (IC50 = 3.4 μM), PTP1B (IC50 = 1.8 μM), and HePTP (IC50 = 1.5 μM). VHR-IN-5 inhibits the proliferation of HeLa cells. VHR-IN-5 can be used for the research of cervical cancer .
Cat. No.: HY-128024
CAS No.: 956189-91-6
Target:
Research Areas:
VHR-IN-1 (Compound SA1) is a potent and selective VHR phosphatase inhibitor with an IC50 of 18 nM. VHR-IN-1 can inhibit the proliferation of cervix cancer cells and has anti-tumor activity .
Cat. No.: HY-RS04064
Target:
Research Areas:
DUSP3 Human Pre-designed siRNA Set A contains three designed siRNAs for DUSP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-135564
CAS No.: 332131-32-5
Target:
RK-682 hemicalcium is the hemicalcium salt form of RK-682 (HY-135564A). RK-682 hemicalcium is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 hemicalcium inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 hemicalcium inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24 [2] .
Cat. No.: HY-P703898
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Dual specificity protein phosphatase 3; DUSP3; Dual specificity protein phosphatase VHR; Vaccinia H1-related phosphatase; VHR
Species:
Source:
Cat. No.: HY-RS17699
Target:
Research Areas:
Dusp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dusp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-124420
CAS No.: 853310-63-1
Target:
Research Areas:
MLS-0322825 is a selective low molecular weight protein tyrosine phosphatase (LMPTP) inhibitor with an IC50 of 3.3 μM for LMPTP-A. MLS-0322825 shows exquisite selectivity over other phosphatases (class I tyrosine-specific lymphoid phosphatase (LYP) and class I dual-specific vaccinia H1-related phosphatase (VHR)). MLS-0322825 can be used for the research of type 2 diabetes [1].
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
